| Title | Major adverse cardiac events at follow-up after bare-metal stenting versus drug-eluting stenting in ST-elevated myocardial infarction. | | Author(s) | Pierre-Louis B, Aronow WS, Palaniswamy C, Singh T, Ahn C, Asija A, Weiss MB, Kalapatapu K, Pucillo AL, Monsen CE | | Institution | Department of Medicine, Cardiology Division, New York Medical College, Valhalla, New York, USA. | | Source | Am J Cardiol 2009 Jun 15; 103(12):1672-4. | | MeSH | Angioplasty, Transluminal, Percutaneous Coronary
Drug-Eluting Stents
Electrocardiography
Female
Follow-Up Studies
Graft Occlusion, Vascular
Humans
Incidence
Male
Middle Aged
Myocardial Infarction
New York
Prognosis
Risk Factors
Survival Rate
Time Factors
| | Abstract | After thrombolytic therapy with tenecteplase for ST-segment elevation acute myocardial infarction, 376 patients were transferred from their hospital to Westchester Medical Center for percutaneous coronary intervention with stenting. Of 376 patients, 102 (27%) received bare-metal stents and 274 (73%) received drug-eluting stents with sirolimus-eluting or paclitaxel-eluting stents. At 43 months of follow-up, major adverse cardiac events occurred in 25 (25%) of 102 patients treated with bare-metal stents versus 40 (15%) of 274 patients treated with drug-eluting stents (p = 0.024). Cox regression analysis showed that significant independent prognostic factors for major adverse cardiac events were previous coronary artery bypass surgery (hazard ratio 2.2, p = 0.019), width of stent (hazard ratio 0.44, p = 0.006), and bare-metal stent (hazard ratio 1.8, p = 0.019). In conclusion, patients with bare-metal stents had a 1.8 times greater risk of developing major adverse cardiac events than did those using drug-eluting stents after controlling the confounding effects of previous coronary artery bypass surgery and stent width. | | Language | eng | | Pub Type(s) | Comparative Study
Journal Article
| | PubMed ID | 19539074 |
|
